A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
<p>Abstract</p> <p>Background</p> <p>Prostate-specific antigen (PSA) is widely used to detect prostate cancer. The low positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies. We set out to determine whether a multivariable mo...
Main Authors: | Scardino Peter T, Pettersson Kim, Becker Charlotte, Pihl Carl-Gustav, Aus Gunnar, Cronin Angel M, Vickers Andrew J, Hugosson Jonas, Lilja Hans |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-07-01
|
Series: | BMC Medicine |
Online Access: | http://www.biomedcentral.com/1741-7015/6/19 |
Similar Items
-
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
by: Villers Arnauld, et al.
Published: (2010-11-01) -
Kallikreins as Biomarkers for Prostate Cancer
by: Sung Kyu Hong
Published: (2014-01-01) -
Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
by: Tomas Bertok, et al.
Published: (2020-10-01) -
Expression of kallikrein-related peptidase 7 is decreased in prostate cancer
by: Chong-Yu Zhang, et al.
Published: (2015-02-01) -
The Value of Low Prostate Imaging—Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies
by: Dong-Soo Kim, et al.
Published: (2021-04-01)